Rating Change
Goldman Sachs analysts reiterated a Buy rating on Enliven Therapeutics, Inc. (NASDAQ:ELVN) on July 21, 2026.
reiterateNASDAQ:ELVN
Goldman Sachs Reiterates Buy Rating on Enliven Therapeutics, Inc. (ELVN)
Rating Change Goldman Sachs analysts reiterated a Buy rating on Enliven Therapeutics, Inc. (NASDAQ:ELVN) on July 21, 2026. Market Context Enliven Therapeutics, Inc.
Market Context
Enliven Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $54.33 with a market capitalization of $1.1B.
Analyst coverage from Goldman Sachs provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Enliven Therapeutics, Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Enliven Therapeutics, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 21, 2026 | Goldman Sachs | Buy | N/A |
| Jul 09, 2026 | HC Wainwright & Co. | Buy | N/A |
| Jul 01, 2026 | Stifel | Buy | N/A |
| Jun 29, 2026 | Jones Trading | Buy | N/A |
| Jun 09, 2026 | Stifel | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View ELVN Stock Page
Frequently Asked Questions
What does a Buy rating mean for ELVN?
A Buy rating from Goldman Sachs reflects the analyst's outlook on Enliven Therapeutics, Inc. (NASDAQ:ELVN). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the ELVN forecast page.
